| Schedule of transition period comparative data |
| |
|
Three months
ended |
|
|
Three months
ended |
|
| |
|
June
30, 2016
(Audited) |
|
|
June
30, 2015
(Unaudited) |
|
| |
|
|
|
|
|
|
| Operating
Data: |
|
|
|
|
|
|
|
|
| Expenses |
|
|
|
|
|
|
|
|
| Research
and development |
|
$ |
709,314 |
|
|
$ |
228,125 |
|
| General
and administrative |
|
|
968,734 |
|
|
|
625,917 |
|
| |
|
|
1,678,048 |
|
|
|
854,042 |
|
| Other
income (expenses) |
|
|
|
|
|
|
|
|
| Grant
income |
|
|
20,500 |
|
|
|
29,999 |
|
| Interest
income |
|
|
186 |
|
|
|
175 |
|
| Change
in fair value of warrant derivative liability |
|
|
(860,275 |
) |
|
|
1,571 |
|
| Total
other income (expenses) |
|
|
(839,589 |
) |
|
|
31,745 |
|
| |
|
|
|
|
|
|
|
|
| Net
loss for the period |
|
$ |
(2,517,637 |
) |
|
$ |
(822,297 |
) |
| |
|
|
|
|
|
|
|
|
| Loss
per share - basic and diluted |
|
$ |
(0.17 |
) |
|
$ |
(0.11 |
) |
| |
|
|
|
|
|
|
|
|
| Weighted average number of shares outstanding
– basic and diluted |
|
|
15,111,088 |
|
|
|
7,823,683 |
|
| |
|
|
|
|
|
|
|
|
| Cash
flow Data: |
|
|
|
|
|
|
|
|
| Net cash used in operating
activities |
|
$ |
(1,100,342 |
) |
|
$ |
(576,492 |
) |
| Net cash used in investing
activities |
|
|
(47,215 |
) |
|
|
(23,378 |
) |
| Net
cash provided by financing activities |
|
|
2,572,896 |
|
|
|
4,241,627 |
|
| Net
increase in cash for the period |
|
$ |
1,425,339 |
|
|
$ |
3,641,757 |
|
|